PMID- 18641372
OWN - NLM
STAT- MEDLINE
DCOM- 20090209
LR  - 20210217
IS  - 0022-2275 (Print)
IS  - 0022-2275 (Linking)
VI  - 49
IP  - 12
DP  - 2008 Dec
TI  - A pilot study of the effects of pioglitazone and rosiglitazone on de novo 
      lipogenesis in type 2 diabetes.
PG  - 2657-63
LID - 10.1194/jlr.M800165-JLR200 [doi]
AB  - Treatment of type 2 diabetes mellitus (T2DM) patients with pioglitazone results 
      in a more favorable lipid profile, and perhaps more favorable cardiac outcomes, 
      than treatment with rosiglitazone. Pioglitazone treatment increases 
      VLDL-triacylglycerol clearance, but the role of de novo lipogenesis (DNL) has not 
      been explored, and no direct comparison has been made between the 
      thiazolidinediones (TZDs). Twelve subjects with T2DM and hypertriacylglyceridemia 
      were randomized to either rosiglitazone or pioglitazone treatment. Stable isotope 
      infusion studies were performed at baseline and after 20 weeks of treatment. Both 
      treatments reduced glucose and HbA(1c) concentrations equally. Pioglitazone 
      treatment resulted in a 40% reduction in hepatic DNL (P < 0.01) and in a 25% 
      reduction in hepatic glucose production (P < 0.05), while rosiglitazone did not 
      significantly change either parameter, although comparisons of changes between 
      treatments were not significantly different. These pilot results indicate that 
      pioglitazone reduces hepatic DNL while rosiglitazone does not. Larger follow-up 
      studies are required to confirm differential effects of these agents 
      definitively. The reduction in DNL may underlie altered assembly or 
      atherogenicity of lipoprotein particles and may reflect PPARalpha or other 
      non-PPARgamma actions on the liver by pioglitazone. These differences might help 
      explain previously reported differences in lipid profiles and cardiovascular 
      disease outcomes for rosiglitazone and pioglitazone.
FAU - Beysen, Carine
AU  - Beysen C
AD  - KineMed, Inc. Emeryville, CA, USA.
FAU - Murphy, Elizabeth J
AU  - Murphy EJ
FAU - Nagaraja, Hirisadarahally
AU  - Nagaraja H
FAU - Decaris, Martin
AU  - Decaris M
FAU - Riiff, Timothy
AU  - Riiff T
FAU - Fong, Alex
AU  - Fong A
FAU - Hellerstein, Marc K
AU  - Hellerstein MK
FAU - Boyle, Patrick J
AU  - Boyle PJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080718
PL  - United States
TA  - J Lipid Res
JT  - Journal of lipid research
JID - 0376606
RN  - 0 (Cholesterol, VLDL)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Thiazolidinediones)
RN  - 05V02F2KDG (Rosiglitazone)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Cholesterol, VLDL/metabolism
MH  - Diabetes Mellitus, Type 2/*metabolism
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/*pharmacology
MH  - Lipogenesis/*physiology
MH  - Male
MH  - Pilot Projects
MH  - Pioglitazone
MH  - Rosiglitazone
MH  - Thiazolidinediones/*pharmacology
EDAT- 2008/07/22 09:00
MHDA- 2009/02/10 09:00
CRDT- 2008/07/22 09:00
PHST- 2008/07/22 09:00 [pubmed]
PHST- 2009/02/10 09:00 [medline]
PHST- 2008/07/22 09:00 [entrez]
AID - S0022-2275(20)34596-X [pii]
AID - 10.1194/jlr.M800165-JLR200 [doi]
PST - ppublish
SO  - J Lipid Res. 2008 Dec;49(12):2657-63. doi: 10.1194/jlr.M800165-JLR200. Epub 2008 
      Jul 18.